Sodium alginate-based drug delivery for diabetes management: A review

Int J Biol Macromol. 2023 May 1:236:123986. doi: 10.1016/j.ijbiomac.2023.123986. Epub 2023 Mar 10.

Abstract

Diabetes mellitus (DM) is among the biggest global health problems of the 21st century, which is characterised by insufficient insulin secretion and results in the augmentation of blood sugar levels. The current foundation of hyperglycemia therapy is oral antihyperglycemic medications like biguanides, sulphonylureas, α-glucosidase inhibitors, peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists, sodium-glucose co-transporter 2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors and others. Many naturally occurring substances have shown promise in treating hyperglycemia. Inadequate prologitivity of action, restricted bioavailability, site specificity, and dose-related side effects are some problems with currently available anti-diabetic medications. Sodium alginate has shown promise as a drug delivery mechanism, potentially solving issues with current therapies for several substances. This review summarizes the research on the efficacy of drug delivery systems based on alginate for transporting oral hypoglycemic medicines, phytochemicals, and insulin for treating hyperglycemia.

Keywords: Diabetes; Drug delivery; Hyperglycemia; Insulin; Polysaccharides; Sodium alginate.

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus, Type 2* / drug therapy
  • Dipeptidyl-Peptidase IV Inhibitors*
  • Humans
  • Hyperglycemia* / chemically induced
  • Hyperglycemia* / drug therapy
  • Hypoglycemic Agents / pharmacology
  • Insulin / therapeutic use
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

  • Hypoglycemic Agents
  • Dipeptidyl-Peptidase IV Inhibitors
  • Insulin
  • Sodium-Glucose Transporter 2 Inhibitors